or vincristine (Bohannon, Miller and Diamond, 1963; Whitelaw and colleagues, 1963 Corticosteroids are also of value for treating the anaemia of cancer. This common complication is in part hiemolytic and the incidence of both anaemia and undue hamolysis increases as the disease progresses. Prednisone or prednisolone in therapeutic doses will often reduce the rate of fall of, and sometimes increases, the hemoglobin level. The explanation for this effect is almost certainly complex but in part may be due to a reduction of losses of red cells from the circulation (Matthias, 1964a) .
There seems little value in using doses of prednisolone or prednisone larger than 40-60 mg. a day in the treatment of malignant disease.
Indeed it has been shown that doses in the range of 250 mg. a day in acute leukaemia are associated with an increased risk of overwhelming infection (Medical Research Council Working Party, 1963) .
The most successful drugs in plasma-cell myeloma are cyclophosphamide (Matthias, Misiewicz and Scott, 1960; Algenstaedt, Gerhartz and Kortge, 1963; Rivers, Whittington and Patno, 1963; Matthias, 1964b) , and melphalan (Bergsagel, Sprague, Austin and Griffith, 1962; Eridani, Carrara and Testero, 1963; Brook, Bateman and Steinfeld, 1964; Waldenstrom, 1964; Speed, Galton and Swan, 1964) . This is possibly explained in part by the fact that either is well tolerated and may be persevered with for considerable periods rather than to any other reason. Some 50-6b% of patients will improve objectively and one third may be returned to gainful occupation.
Busulphan induces consistent and worthwhile remissions in chronic myelocytic leukaemia. It is more easily controlled and more consistent than mercaptopurine (Shullenberger, 1961) tary system has proved extremely resistant to therapy, although it is claimed that successful palliation may be achieved in 20-30% with 5-fluorouracil or related compounds (Wilson, 1960; Ansfield and Curreri, 1963 (Moore, 1958; Sears, 1961) , methotrexate (Wright, Cobb, Golomb, Gumport, Lyall and Safadi, 1959) or 5-fluorouracil (Ivy, 1962; Dao and Grinberg, 1963) (Balme, 1954; Crile, 1957; Thomas, 1957 (Baker, 1961) (Peters, 1950; Peters and Middlemiss, 1958 (Noer, 1962) , thiotepa and surgery in ovarian carcinoma (Masterton, 1962) , actinomycin D and radiation in Wilm's tumour (Farber, D'Angio, 1vans and Mitus, 1960; Altman, 1961) , and tretamine (TEM) and radiation in retinoblastoma (Reese and (Hertz and colleagues, 1959 (Hertz and colleagues, , 1961 (Hertz and colleagues, , 1963 Bagshaw, 1963 Experimental work, however, suggests that tumours contain a spectrum of cells of varying sensitivity and that it becomes progressively more difficult to destroy all the neoplastic cells (Hauschka, 1957) . There is evidence that the higher the dose the more effective the treatment (Ferrebee and Thomas, 1960; Skipper, Schabel and Wilcox, 1964) (Mathe, 1960; Kurnick, 1962) . It seems that ultimate recovery is little improved even following the use of autologous marrow although the rate of recovery may be accelerated (Sprague, 1960) . The administration of testosterone may allow larger doses of chemotherapeutic drugs to be given with less than the expected degree of depression of the peripheral count (Brodsky, Dennis and Khan, 1964 (Martin, 1960 (Graham and Graham, 1959; Buinaskos, McCredie, Brown and Cole, 1959 (Sullivan, Miller and Sykes, 1959; Duff and colleagues, 1961; Trussell and Mitford-Barberton, 1961) , thymidine with 5-fluorodeoxyuridine (Miller, Sullivan, Young and Burchenal, 1961) , and thiosulphate or cysteine when using radiomimetic drugs. Protection of the body may also be attempted by hypothermia.
The second method is that of perfusion (Creech, 1959, a and b (Rose and Nelson, 1955; Sullivan and Zurek, 1964 May, 1965 273
